KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Receivables (2016 - 2025)

Historic Receivables for Novartis Ag (NVS) over the last 13 years, with Q4 2025 value amounting to $10.1 billion.

  • Novartis Ag's Receivables rose 1828.64% to $10.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.1 billion, marking a year-over-year increase of 1828.64%. This contributed to the annual value of $10.1 billion for FY2025, which is 1828.64% up from last year.
  • Novartis Ag's Receivables amounted to $10.1 billion in Q4 2025, which was up 1828.64% from $8.5 billion recorded in Q4 2024.
  • Novartis Ag's 5-year Receivables high stood at $10.1 billion for Q4 2025, and its period low was $8.4 billion during Q4 2023.
  • For the 5-year period, Novartis Ag's Receivables averaged around $8.9 billion, with its median value being $8.7 billion (2021).
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 736.92% in 2023, then surged by 1828.64% in 2025.
  • Novartis Ag's Receivables (Quarter) stood at $8.8 billion in 2021, then rose by 2.57% to $9.0 billion in 2022, then dropped by 7.37% to $8.4 billion in 2023, then rose by 1.93% to $8.5 billion in 2024, then rose by 18.29% to $10.1 billion in 2025.
  • Its Receivables stands at $10.1 billion for Q4 2025, versus $8.5 billion for Q4 2024 and $8.4 billion for Q4 2023.